

## Supplementary material

**Table S1.** Survey results grouped by drugs.

	Mushrooms	LSD or analog	Ayahuasc a	DMT	5meo-DMT	San Pedro	Bufo Alvarius	Total users	Total non-users	Total sample
<b>Demographics</b>										
% (n)		30.24 (1699)	1.25 (70)	2.79 (157)	0.57 (32)	1.51 (85)	0.12 (7)	32.43 (1822)	67.57 (3796)	(5618)
Female (%)	52.70	63.21	62.86	61.15	75.00	54.12	42.86	63.17	76.19	71.97
Male (%)	47.30	36.79	37.14	38.85	25.00	45.88	57.14	36.83	23.81	28.03
Age (mean ± sem)	28.89 ±0.28	27.41 ± 0.16	33.81 ± 1.00	27.54 ± 0.47	29.50 ± 1.12	31.52 ± 0.82	38.00 ± 4.42	27.66 ± 0.16	29.86 ± 0.16	29.15 ± 0.12
Psych. assist. (%)	66.37	66.22	68.57	66.24	68.75	62.35	71.43	65.81	59.19	61.34
Hospitalization (%)	1.26	1.53	2.86	3.18	9.38	1.18	14.29	1.54	1.03	1.19
Medication (%)	5.76	5.59	10.00	6.37	9.38	2.35	28.57	5.43	5.64	5.57
<b>STAI</b>										
State anxiety	24.74 ±0.48	25.75 ± 0.27	23.97 ± 1.37	25.87 ± 0.97	25.88 ± 2.22	24.06 ± 1.32	26.86 ± 3.98	25.67 ± 0.26	26.17 ± 0.19	26.01 ± 0.15
Trait anxiety	25.59 ± 0.48	26.78 ± 0.27	24.86 ± 1.37	27.03 ± 0.97	27.66 ± 2.22	24.54 ± 1.32	28.14 ± 3.98	26.61 ± 0.26	26.26 ± 0.19	26.37 ± 0.15

PANAS										
Negative affect	21.81	22.66	21.46	22.49	24.09	21.93	22.14	22.57	22.18	22.31
	± 0.32	± 0.19	± 0.96	± 0.59	± 1.35	± 0.88	± 3.36	± 0.18	± 0.13	± 0.10
Positive affect	29.35	28.63	31.07	28.97	29.34	31.02	30.14	28.71	28.99	28.90
	± 0.33	± 0.19	± 0.96	± 0.66	± 1.61	± 0.89	± 3.83	± 0.18	± 0.13	± 0.11

BIEPS										
Acceptance	7.59	7.50	7.69	7.50	7.44	7.72	8.14	7.52	7.56	7.55
	± 0.06	± 0.03	± 0.16	± 0.12	± 0.25	± 0.13	± 0.26	± 0.03	± 0.02	± 0.02
Autonomy	6.77	6.61	7.09	6.84	6.91	6.99	7.43	6.62	6.58	6.59
	± 0.07	± 0.04	± 0.19	± 0.13	± 0.27	± 0.16	± 0.53	± 0.04	± 0.03	± 0.02
Social ties	8.18	8.12	8.41	7.94	7.69	8.32	7.86	8.12	8.02	8.05
	± 0.05	± 0.03	± 0.11	± 0.11	± 0.27	± 0.11	± 0.55	± 0.03	± 0.02	± 0.02
Goals	9.92	9.95	10.17	10.02	10.41	10.26	10.71	9.97	10.05	10.03
	± 0.08	± 0.04	± 0.23	± 0.14	± 0.28	± 0.19	± 0.36	± 0.04	± 0.03	± 0.02
Total Well-being	32.46	32.19	33.36	32.29	32.44	33.28	34.14	32.23	32.21	32.22
	± 0.17	± 0.10	± 0.44	± 0.34	± 0.75	± 0.40	± 1.28	± 0.09	± 0.07	± 0.05

RS										
Self-reliance	57.55	56.81	58.31	56.99	57.06	57.92	60.43	56.89	57.16	57.07
	± 0.38	± 0.22	± 1.01	± 0.77	± 1.76	± 0.90	± 3.75	± 0.21	± 0.16	± 0.13
Meaning	22.57	22.21	23.10	22.48	23.56	22.72	22.71	22.27	23.09	22.82
	± 0.22	± 0.12	± 0.59	± 0.39	± 0.86	± 0.52	± 2.36	± 0.12	± 0.08	± 0.07

Cognitive	17.55	17.44	17.61	17.28	17.31	17.48	20.43	17.52	17.88	17.76
avoidance	± 0.20	± 0.11	± 0.59	± 0.40	± 0.89	± 0.46	± 1.07	± 0.11	± 0.08	± 0.06
Total	97.67	96.4	99.03	96.75	97.94	98.12	103.57	96.68	98.12	97.66
Resilience	± 0.66	7 ± 0.37	± 1.79	± 1.23	± 2.90	± 1.45	± 6.16	± 0.36	± 0.26	± 0.21
<b>BFI</b>										
Extraversion	26.59	26.41	26.93	26.81	26.31	26.60	26.71	26.39	25.56	25.83
	± 0.26	± 0.15	± 0.65	± 0.47	± 0.97	± 0.64	± 2.24	± 0.14	± 0.10	± 0.08
Agreeableness	32.54	32.46	32.81	32.00	32.00	33.01	33.14	32.51	32.88	32.76
	± 0.21	± 0.12	± 0.61	± 0.39	± 0.86	± 0.48	± 0.86	± 0.12	± 0.08	± 0.07
Conscientiousness	29.29	28.88	30.11	28.61	29.81	28.26	26.14	28.96	30.87	30.25
	± 0.28	± 0.16	± 0.81	± 0.52	± 1.22	± 0.74	± 2.79	± 0.15	± 0.11	± 0.09
Neuroticism	24.97	25.66	24.66	25.70	25.53	24.18	23.71	25.57	25.84	25.75
	± 0.28	± 0.16	± 0.73	± 0.50	± 1.32	± 0.65	± 2.20	± 0.15	± 0.11	± 0.09
Openness	40.30	39.60	41.24	41.34	41.81	41.62	42.00	39.60	37.89	38.44
	± 0.25	± 0.15	± 0.71	± 0.44	± 0.83	± 0.59	± 2.30	± 0.14	± 0.11	± 0.09
Alpha factor	76.87	75.68	78.27	74.91	76.28	77.09	75.57	75.90	77.91	77.26
	± 0.54	± 0.31	± 1.40	± 1.00	± 2.19	± 1.24	± 3.88	± 0.30	± 0.21	± 0.17
Beta factor	66.89	66.00	68.17	68.15	68.12	68.22	68.71	65.99	63.45	64.27
	± 0.39	± 0.23	± 1.07	± 0.69	± 1.42	± 0.95	± 3.77	± 0.22	± 0.16	± 0.13

**Table S1.** The information shown corresponds to the sample subset (participants older than 18 years old, Argentinians, who live in Argentina, with male or female gender identity). Consumers in each user group are not mutually exclusive with the other groups (users in each group may have used more than one drug).